


1
2
3
4
5
6
7
8
9
10
11
12
13

Supplemental Figure 1. (A) TFEB fluorescence intensity in HK-2 cells infected with empty (LV-NC) or *TFEB*-S142A/S211A overexpressing lentivirus (LV-*TFEB* Mut) was quantified (n=3). (B) TFEB expression levels in HK-2 cells infected with LV-NC or LV-*TFEB* Mut were normalized to H3 (n=3). (C, D) *LAMP1* and *CTSD* mRNA levels in LV-NC and LV-*TFEB* Mut cells were determined by qPCR (n=3). (E) Cell viability of HK-2 cells treated with different concentrations of tacrolimus (25, 50, 75 μ M). (F) TFEB expression levels in HK-2 cells infected with LV-NC or LV-*TFEB* Mut treated with or without tacrolimus were normalized to H3 (n=3). Data are shown as mean \pm SD and analyzed by two-tailed Student's t-tests (A-D) and one-way ANOVA (E and F). *P < 0.05, **P < 0.01, ***P < 0.001.



14

15 **Supplemental Figure 2. TICN was alleviated by the activation of TFEB by torin**
 16 **1 in vivo.** (A) TFEB nuclear translocation in kidney tissues of mice treated with
 17 vehicle or Torin 1 was evaluated by western blot (n=3). (B) The kidney/body weight
 18 ratio of mice was recorded (n=6). The levels of (C) serum creatinine and (D) blood
 19 urea nitrogen in mice were determined with commercial kits (n=6). (E)
 20 Representative images of H&E- and Masson-stained kidney sections (scale bar, 50
 21 μm), as well as TGF-β immunohistochemical staining (scale bar, 20 μm). (F) The
 22 proportion of tubulointerstitial fibrosis in mouse renal tissue stained by Masson was
 23 quantified (n=6). (G) *Colla1* mRNA and (H) α-SMA protein in mouse renal tissue
 24 was measured by qPCR and western blot, respectively (n=3). Data are shown as mean
 25 ± SD and analyzed by two-tailed Student's t-tests (A) and one-way ANOVA (B-D
 26 and F-H). *P < 0.05, **P < 0.01, ***P < 0.001.

27

28


29

30 **Supplemental Table.** The overlapping genes of TFEB direct target genes identified in
31 human embryonic kidney 293 cells^[23] and differentially expressed genes in the
32 kidneys of wild-type or kidney-specific TFEB overexpressed mice^[24]

<i>Actr1a</i>	<i>Gadd45g</i>	<i>Pim1</i>	<i>Soat1</i>
<i>Atf5</i>	<i>Hsd11b2</i>	<i>Rabgef1</i>	<i>Specc1</i>
<i>Cdc25b</i>	<i>Il11</i>	<i>Rps6ka1</i>	<i>Tbc1d14</i>
<i>Cln3</i>	<i>Itfg2</i>	<i>Scamp5</i>	<i>Tbx3</i>
<i>Cyp2s1</i>	<i>Map3k1</i>	<i>Sfxn3</i>	<i>Tmprss2</i>
<i>Eral1</i>	<i>Mlph</i>	<i>Slc20a1</i>	<i>Trib3</i>
<i>Gadd45a</i>	<i>Pdgfa</i>	<i>Slc38a1</i>	<i>Wdfy1</i>

33

34




35

36 **Supplemental Figure 3.** (A) GADD45 α expression levels in mice treated with
37 vehicle or tacrolimus were quantified (n=3). (B) TFEB expression levels in HK-2
38 cells infected with LV-NC or LV-*TFEB* Mut were normalized to H3 (n=3). (C) TFEB
39 expression levels in HK-2 cells infected with shNC or sh*TFEB* were normalized to H3
40 (n=3). Data are shown as mean \pm SD and analyzed by two-tailed Student's t-tests. *P
41 < 0.05, **P < 0.01, ***P < 0.001.

42

43



44

45 **Supplemental Figure 4.** Densitometric analysis of **(A)** TFEB and **(B)** GADD45α
 46 blots in HK-2 cells transfected with control vectors, *TFEB* shRNA, *LV-GADD45A* or
 47 combination of the latter two and then treated with Tac (50 μM for 24 h) (n=3).
 48 Densitometric analysis of **(C)** TFEB and **(D)** GADD45α blots in HK-2 cells
 49 transfected with control vectors, *LV-TFEB* Mut, *shGADD45A* or combination of the
 50 latter two and then treated with Tac (50 μM for 24 h) (n=3). Data are shown as mean ±
 51 SD and analyzed by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.